Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novo Nordisk
Biotech
Novo Nordisk discards $1.3B kidney drug in wake of phase 3 fail
Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 billion deal.
James Waldron
Nov 6, 2024 4:54am
In $285M deal, Novo taps Ascendis to help create monthly GLP-1
Nov 4, 2024 8:43am
Novo obesity prospect linked to ‘neuropsychiatric side effects’
Sep 20, 2024 10:25am
Novo inks $600M NanoVation deal to study genetic drugs ex-liver
Sep 18, 2024 9:03am
Novo Nordisk signs $530M biobucks deal to sing in Korro's opera
Sep 16, 2024 9:40am
Novo hails ‘remarkable’ weight loss result for experimental pill
Sep 11, 2024 11:02am
